Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1520-27-0

Post Buying Request

1520-27-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1520-27-0 Usage

Description

1-(4-HYDROXYPHENYL)-2-THIOUREA, also known as 1-(4-Hydroxyphenyl)thiourea, is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its unique molecular structure, which includes a thiourea group attached to a phenyl ring with a hydroxyl group at the para position. This structure endows it with specific chemical properties and reactivity, making it a valuable building block in the development of novel therapeutic agents.

Uses

Used in Pharmaceutical Synthesis:
1-(4-HYDROXYPHENYL)-2-THIOUREA is used as an intermediate in the synthesis of SKI II, a nonlipid inhibitor of sphingosine kinase. 1-(4-HYDROXYPHENYL)-2-THIOUREA has demonstrated significant inhibition of tumor growth in mice, making it a promising candidate for the development of anticancer drugs.
SKI II is an orally bioavailable compound that targets sphingosine kinase, an enzyme involved in the regulation of cell survival, proliferation, and migration. By inhibiting this enzyme, SKI II can potentially disrupt the signaling pathways that contribute to the growth and progression of cancer cells.
In the pharmaceutical industry, 1-(4-HYDROXYPHENYL)-2-THIOUREA plays a vital role in the development of new drugs with potential applications in cancer treatment. Its unique chemical properties and reactivity make it an attractive starting material for the synthesis of novel therapeutic agents that can target various aspects of cancer biology.

Check Digit Verification of cas no

The CAS Registry Mumber 1520-27-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,5,2 and 0 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1520-27:
(6*1)+(5*5)+(4*2)+(3*0)+(2*2)+(1*7)=50
50 % 10 = 0
So 1520-27-0 is a valid CAS Registry Number.
InChI:InChI=1/C7H8N2OS/c8-7(11)9-5-1-3-6(10)4-2-5/h1-4,10H,(H3,8,9,11)

1520-27-0 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (L12537)  N-(4-Hydroxyphenyl)thiourea, 98+%   

  • 1520-27-0

  • 1g

  • 393.0CNY

  • Detail
  • Alfa Aesar

  • (L12537)  N-(4-Hydroxyphenyl)thiourea, 98+%   

  • 1520-27-0

  • 5g

  • 1303.0CNY

  • Detail

1520-27-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name N-(4-Hydroxyphenyl)Thiourea

1.2 Other means of identification

Product number -
Other names (4-hydroxyphenyl)thiourea

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1520-27-0 SDS

1520-27-0Relevant articles and documents

Synthesis and biological evaluation of 2-(3,4-dimethoxyphenyl)-6-(2-[18F]fluoroethoxy)benzothiazole ([18F]FEDBT) for PET imaging of breast cancer

Li, Geng-Ying,Vaulina, Daria D.,Li, Jia-Je,Fedorova, Olga S.,Wang, Hsin-Ell,Liu, Ren-Shyan,Krasikova, Raisa N.,Chen, Chuan-Lin

, p. 3460 - 3463 (2017)

Given the ever-present demand for improved PET radiotracer in oncology imaging, we have synthesized 2-(3,4-dimethoxyphenyl)-6-(2-[18F]fluoroethoxy)benzothiazole ([18F]FEDBT), a fluorine-18-containing fluoroethylated benzothiazole to explore its utility as a PET imaging tracer. [18F]FEDBT was prepared via kryptofix-mediated nucleophilic substitution of the tosyl group precursor. Fractionated ethanol-based solid-phase (SPE cartridge-based) purification afforded [18F]FEDBT in 60% radiochemical yield (EOB), with radiochemical purity in excess of 98% and the specific activity was 35?GBq/μmol. The radiotracer displayed clearly higher cellular uptake ratio in various breast cancer cell lines MCF7, MDA-MB-468 and MDA-MB-231. However, both biodistribution and microPET studies have showed an higher abdominal accumulation of [18F]FEDMBT and the tumor/muscle ratio of 1.8 was observed in the MDA-MB-231 xenograft tumors mice model. Further the lipophilic improvement is needed for the reducement of hepatobilliary accumulation and to promote the tumor uptake for PET imaging of breast cancer.

Effect of N-1 arylation of monastrol on kinesin Eg5 inhibition in glioma cell lines

Gon?alves, Itamar Luís,Rockenbach, Liliana,Das Neves, Gustavo Machado,G?ethel, Gabriela,Nascimento, Fabiana,Porto Kagami, Luciano,Figueiró, Fabrício,Oliveira De Azambuja, Gabriel,De Fraga Dias, Amanda,Amaro, Andressa,De Souza, Lauro Mera,Da Rocha Pitta, Ivan,Avila, Daiana Silva,Kawano, Daniel Fábio,Garcia, Solange Cristina,Battastini, Ana Maria Oliveira,Eifler-Lima, Vera Lucia

, p. 995 - 1010 (2018/06/27)

An original and focused library of two sets of dihydropyrimidin-2-thiones (DHPMs) substituted with N-1 aryl groups derived from monastrol was designed and synthesized in order to discover a more effective Eg5 ligand than the template. Based on molecular docking studies, four ligands were selected to perform pharmacological investigations against two glioma cell lines. The results led to the discovery of two original compounds, called 20h and 20e, with an anti-proliferative effects, achieving IC50 values of about half that of the IC50 of monastrol in both cell lines. As with monastrol, flow cytometry analyses showed that the 20e and 20h compounds induced cell cycle arrest in the G2/M phase, and immunocytochemistry essays revealed the formation of monopolar spindles due to Eg5 inhibition without any toxicity to Caenorhabditis elegans.

Synergism of fused bicyclic 2-aminothiazolyl compounds with polymyxin B against: Klebsiella pneumoniae

Wang, Rong,Hou, Shuang,Dong, Xiaojing,Chen, Daijie,Shao, Lei,Qian, Liujia,Li, Zhong,Xu, Xiaoyong

supporting information, p. 2060 - 2066 (2017/11/22)

A series of fused bicyclic 2-aminothiazolyl compounds were synthesized and evaluated for their synergistic effects with polymyxin B (PB) against Klebsiella pneumoniae (SIPI-KPN-1712). Some of the synthesized compounds exhibited synergistic activity. When 4 μg ml-1 compound B1 was combined with PB, it showed potent antibacterial activity, achieving 64-fold reduction of the MIC of PB. Furthermore, compound B1 showed prominent synergistic efficacy in both concentration gradient and time-kill curves in vitro. In addition, B1 combined with PB also exhibited synergistic and partial synergistic effect against E. coli (ATCC25922 and its clinical isolates), Acinetobacter baumannii (ATCC19606 and its clinical isolates), and Pseudomonas aeruginosa (Pae-1399).

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1520-27-0